Global Leukapheresis Market

Leukapheresis Market Size, Share, Growth Analysis, By Product Type(Leukapheresis devices and leukapheresis disposables), By Application(Leukemia, lymphoma), By End user(Hospitals and blood component centers, pharmaceutical and biotechnology companies) - Industry Forecast 2024-2031


Report ID: SQMIG35B2173 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 88 | Figures: 76

Leukapheresis Market Insights

Leukapheresis Market size was valued at USD 65.60 billion in 2021 and is poised to grow from USD 71.44 billion in 2022 to USD 141.30 billion by 2030, growing at a CAGR of 8.9% during the forecast period (2023-2030).

Global Leukapheresis Market is a vital and rapidly expanding sector within the medical industry, offering critical therapeutic and diagnostic solutions for various diseases. Leukapheresis involves the selective separation and collection of white blood cells (leukocytes) from the blood, enabling their use in treatments, research, and diagnostics. The purpose of the leukapheresis market is to provide healthcare professionals with a valuable tool for the management and treatment of diseases that involve abnormal white blood cell counts or activities. This includes conditions such as leukemia, lymphoma, autoimmune disorders, and certain neurological diseases. Leukapheresis procedures allow for the removal of excessive or malfunctioning white blood cells while preserving other components of the blood, thereby helping to restore a healthier balance.

The market is driven by several factors. Firstly, the increasing prevalence of hematologic disorders and autoimmune diseases has heightened the demand for leukapheresis procedures. According to research, the global incidence of blood cancers and autoimmune disorders has been steadily rising, necessitating effective treatment approaches such as leukapheresis. Moreover, advancements in leukapheresis technologies and techniques have enhanced the safety and efficacy of the procedure, further fueling market growth. Innovative automated systems and improved apheresis machines enable better control, precision, and scalability, making leukapheresis a reliable and widely applicable therapy.

However, the leukapheresis market also faces certain restraints. Limited awareness among healthcare providers and patients about the potential benefits of leukapheresis procedures could hinder market growth. Additionally, the high cost associated with leukapheresis devices and consumables, along with the requirement for specialized healthcare personnel, may limit accessibility, particularly in developing regions. Key trends in the leukapheresis market include the development of personalized medicine approaches and the integration of leukapheresis with other therapies. Personalized medicine aims to tailor treatments to individual patients based on their specific disease characteristics, and leukapheresis plays a crucial role in obtaining patient-specific samples for diagnostics and research.

Furthermore, there are significant opportunities in the leukapheresis market. The increasing research and development activities in the field of immunotherapy and cell-based therapies offer promising avenues for leukapheresis. These therapies, such as chimeric antigen receptor (CAR) T-cell therapy, rely on the collection and manipulation of patient-derived white blood cells, making leukapheresis a vital component in their implementation. Additionally, the growing focus on precision medicine, advancements in apheresis technology, and expanding healthcare infrastructure in developing regions present opportunities for market expansion. Market players can leverage these opportunities by investing in research, raising awareness, and developing cost-effective leukapheresis solutions that meet the specific needs of different patient populations.

US Leukapheresis Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Leukapheresis Market size was valued at USD 65.60 billion in 2021 and is poised to grow from USD 71.44 billion in 2022 to USD 141.30 billion by 2030, growing at a CAGR of 8.9% during the forecast period (2023-2030).

Leukapheresis Market features a highly competitive landscape with the presence of several key players striving to gain a larger market share. Companies in this market are focused on product development, strategic collaborations, mergers and acquisitions, and geographic expansion to strengthen their position in the market. Some prominent players in the leukapheresis market are consistently investing in research and development activities to introduce innovative leukapheresis products and technologies. They are also engaged in partnerships and collaborations with healthcare institutions and research organizations to further expand their product offerings and explore new market opportunities. With the increasing prevalence of blood-related disorders and the rising demand for leukapheresis procedures, the competitive landscape of the leukapheresis market is expected to witness further advancements and intense competition among the key market players. 'Terumo BCT Corporation (US)', 'Asahi Kasei Medical Co., Ltd. (Japan)', 'Fresenius SE & Co. KGaA (Germany)', 'Haemonetics Corporation (US)', 'Macopharma SA (France)', 'Miltenyi Biotec GmbH (Germany)', 'STEMCELL Technologies Inc. (Canada)', 'Cytiva (US)', 'Beijing ZKSK Technology Co., Ltd. (China)', 'Grifols, S.A. (Spain)', 'Kaneka Corporation (Japan)', 'Medica SpA (Italy)', 'B. Braun Melsungen AG (Germany)', 'Immucor, Inc. (US)', 'Bioelettronica S.r.l. (Italy)', 'Fresenius Kabi AG (Germany)', 'Qingdao Huarui Biological Technology Co., Ltd. (China)', 'Miltenyi Biotec B.V. & Co. KG (Netherlands)', 'Therakos, Inc. (US)', 'Pluristem Therapeutics Inc. (Israel)'

The rising incidence of hematologic disorders, such as leukemia and lymphoma, is a significant driver for the leukapheresis market. These diseases require effective treatment approaches, and leukapheresis plays a crucial role in managing abnormal white blood cell counts. For example, in cases of acute leukemia, leukapheresis can rapidly reduce the number of leukemic cells in the blood to alleviate symptoms and prepare patients for subsequent therapies.

Integration of Leukapheresis with Cell-Based Therapies: Leukapheresis is increasingly integrated with cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy involves the collection and genetic modification of a patient's own white blood cells, which are then infused back into the patient to target and eliminate cancer cells. Leukapheresis plays a vital role in obtaining the required cells for CAR T-cell therapy, making it an integral part of the treatment process.

North America dominated the leukapheresis market, driven by advanced healthcare infrastructure, strong research and development capabilities, and high adoption of innovative medical technologies. The region benefits from the presence of key market players, academic institutions, and research centers focused on advancing leukapheresis procedures. For instance, the United States dominates the North American market with a considerable market share. The country's well-established healthcare system, supportive regulatory environment, and increasing prevalence of hematologic disorders contribute to the market's dominance. Another dominating region is Europe, which holds a significant market share in the leukapheresis market. European countries such as Germany, France, and the United Kingdom have well-developed healthcare systems and robust research activities. These countries have a high adoption rate of advanced medical technologies and a strong focus on precision medicine, which drives the demand for leukapheresis procedures.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Leukapheresis Market

Product ID: SQMIG35B2173

$5,300
BUY NOW GET FREE SAMPLE